Cargando…
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
BACKGROUND: Tumor dynamics typically rely on the sum of the longest diameters (SLD) of target lesions, and ignore heterogeneity in individual lesion dynamics located in different organs. PATIENTS AND METHODS: Here we evaluated the benefit of analyzing lesion dynamics in different organs to predict s...
Autores principales: | Kerioui, M., Desmée, S., Mercier, F., Lin, A., Wu, B., Jin, J.Y., Shen, X., Le Tourneau, C., Bruno, R., Guedj, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718952/ https://www.ncbi.nlm.nih.gov/pubmed/34954496 http://dx.doi.org/10.1016/j.esmoop.2021.100346 |
Ejemplares similares
-
Disease Control with Prior Platinum-based Chemotherapy Is Prognostic for Survival in Patients with Metastatic Urothelial Cancer Treated with Atezolizumab in Real-world Practice
por: Mencinger, Marina, et al.
Publicado: (2021) -
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023) -
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
por: Küronya, Zsófia, et al.
Publicado: (2022) -
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018) -
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)